Potential new chemotherapy for breast cancer therapy with a novel KSP inhibitor

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10074
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: St. Marianna University School of Medicine
• Principal Investigator: Ohta Yuki 聖マリアンナ医科大学, 医学部, 講師 (60387066)
• Co-Investigator(Kenkyū-buntansha): 武永 美津子 聖マリアンナ医科大学, 医学(系)研究科(研究院), 教授 (10236490) ; 大滝 正訓 聖マリアンナ医科大学, 医学部, 助教 (20612683)
• Co-Investigator(Renkei-kenkyūsha): FUJII Nobutaka 京都大学, 薬学部, 教授 (60109014) ; OISHI Shinya 京都大学, 薬学部, 准教授 (80381739)
• Research Collaborator: TSUCHIYA Seiko ; NIIMI Jun
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: kinesin spindle protein / 乳癌 / 微小管阻害薬 / 末梢神経障害

Outline of Final Research Achievements

Among the novel synthetic KSP inhibitors, KPYB 10602 has the highest inhibitory effect on cell proliferation against human breast cancer cell lines, and its effect was highest in MDA-MB-231 cells. The KPYB10602 treatment was shown to result in induction of mitotic arrest with distinct monopolar spindle formation and then apoptotic cell death. KPYB10602 also effectively suppressed tumor growth in a subcutaneous xenograft model. In conclusion, KSP is a good target for breast cancer chemotherapy, and KPYB10602 has a potential as a novel anti-cancer agent for breast cancer.

Free Research Field

医歯薬学